Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure | Synapse

July 26, 2011Open Access

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Outcome after AZA failure is poor. Our results should serve as a basis for designing second-line clinical trials in this population.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Prébet et al. (Tue,) studied this question.

synapsesocial.com/papers/69ecef1dd55980bedc8fe5b3 https://doi.org/https://doi.org/10.1200/jco.2011.35.8135

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency1995 · 5 citations
2Translating the Histone Code2001 · 9,677 citations
3Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia2003 · 2,664 citations
4A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older2009 · 145 citations
5Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study2009 · 2,646 citations